EGFR and breast cancer: As EGFR has been identified as a promising target for cancer patients for some time, several potent drugs, (e.g. Gefitinib, Erlotinib, Cetuximab, Lapatinib etc.), all approved for the treatment of cancer patients, have been tested in clinical breast cancer studies with overall disappointing results [4].